Outcomes by Race in Breast Cancer Screening With Digital Breast Tomosynthesis Versus Digital Mammography

Alsheik, Nila; Blount, Linda Goler; Qiu, Qiong; Talley, Melinda; Pohlman, Scott; Troeger, K.A.; Abbey, Genevieve; Mango, Victoria L.; Pollack, Erica; Chong, Alice; Donadio, Greg; Behling, Michael; Mortimer, Kathleen; Conant, Emily F.

doi:10.1016/j.jacr.2020.12.033

Cited by 26 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Although Black and White women have similar self-reported mammography prevalence (Table 8), Black women are more likely to overreport screening 76 and are less likely to have imaging at a facility with the most current technology, such as digital breast tomosynthesis. 77 However, Black women have lower survival at every stage of diagnosis because of barriers in the timely receipt of high-quality treatment. 78 A study in North Carolina found that Black women experienced delays compared with White women not only in the initiation of treatment but throughout the treatment experience.…”

Section: Tablementioning

confidence: 99%

“…A recent study found that almost one‐half of the disparity in stage at diagnosis is because of differences in insurance coverage 9 . Although Black and White women have similar self‐reported mammography prevalence (Table 8), Black women are more likely to overreport screening 76 and are less likely to have imaging at a facility with the most current technology, such as digital breast tomosynthesis 77 . However, Black women have lower survival at every stage of diagnosis because of barriers in the timely receipt of high‐quality treatment 78 .…”

Section: Selected Cancer Sitesmentioning

confidence: 99%

See 1 more Smart Citation

Cancer statistics for African American/Black People 2022

Giaquinto

Miller

Tossas

et al. 2022

CA A Cancer J Clinicians

391

228

View full text Add to dashboard Cite

African American/Black individuals have a disproportionate cancer burden, including the highest mortality and the lowest survival of any racial/ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2018), mortality (through 2019), survival, screening, and risk factors using population‐based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2022, there will be approximately 224,080 new cancer cases and 73,680 cancer deaths among Black people in the United States. During the most recent 5‐year period, Black men had a 6% higher incidence rate but 19% higher mortality than White men overall, including an approximately 2‐fold higher risk of death from myeloma, stomach cancer, and prostate cancer. The overall cancer mortality disparity is narrowing between Black and White men because of a steeper drop in Black men for lung and prostate cancers. However, the decline in prostate cancer mortality in Black men slowed from 5% annually during 2010 through 2014 to 1.3% during 2015 through 2019, likely reflecting the 5% annual increase in advanced‐stage diagnoses since 2012. Black women have an 8% lower incidence rate than White women but a 12% higher mortality; further, mortality rates are 2‐fold higher for endometrial cancer and 41% higher for breast cancer despite similar or lower incidence rates. The wide breast cancer disparity reflects both later stage diagnosis (57% localized stage vs 67% in White women) and lower 5‐year survival overall (82% vs 92%, respectively) and for every stage of disease (eg, 20% vs 30%, respectively, for distant stage). Breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in 2019. Targeted interventions are needed to reduce stark cancer inequalities in the Black community.

show abstract

Section: Tablementioning

confidence: 99%

Section: Selected Cancer Sitesmentioning

confidence: 99%

Cancer statistics for African American/Black People 2022

Giaquinto

Miller

Tossas

et al. 2022

CA A Cancer J Clinicians

391

228

View full text Add to dashboard Cite

show abstract

“…In the US, patients living in rural and low socioeconomic status zip-codes have lower rates of breast cancer screening [ 7 ]. African American and Hispanic women are significantly less likely to receive DBT, which is associated with superior breast cancer detection [ 15 ]. African American and non-English-speaking patients were also less likely to receive timely notification and follow-up of abnormal mammography results, which poses a higher risk for morbidity and mortality [ 16 , 17 ].…”

Section: Breast Cancermentioning

confidence: 99%

US Cancer Screening Recommendations: Developments and the Impact of COVID-19

Barsouk

Saginala²,

Aluru

et al. 2022

Medical Sciences

View full text Add to dashboard Cite

The USPSTF and ACS recommend screening for breast, cervical, colorectal, and lung cancers. Rates of cancer screening, diagnosis, and treatment decreased significantly in the US and other developed nations during the height of the COVID-19 pandemic and lockdown (April 2020) and have since recovered, although not to baseline levels in many cases. For breast cancer, the USPSTF recommends biennial screening with mammography for women aged 50–74, while the ACS recommends annual screening for women aged 45–54, who may transition to biennial after 55. Minority and rural populations have lower rates of screening and lower utilization of DBT, which offers superior sensitivity and specificity. Among 20 US health networks in April 2020, mammography rates were down 89.2% and new breast cancer diagnoses down by 50.5%. For cervical cancer, the USPSTF recommends cervical cytology every three years for women 21–65, or cytology+hrHPV co-testing every five years for women aged 30–65. Cervical cancer screening rates declined by 87% in April 2020 and recovered to a 40% decline by June 2020, with American Indians and Asians most severely affected. For colorectal cancer (CRC), the USPSTF and ACS recommend screening for ages 45–75, recently lowered from a starting age of 50. Most commonly-used modalities include annual FIT testing, FIT+DNA testing every three years, and colonoscopy every ten years, with shorter repeat if polyps are found. In the US, CRC screenings were down by 79–84.5% in April 2020 across several retrospective studies. Patient encounters for CRC were down by 39.9%, and a UK-based model predicted that 5-year-survival would decrease by 6.4%. The USPSTF recommends screening low dose CT scans (LDCTs) for ages 50–80 with a >20 pack-year smoking history who have smoked within the past 15 years. In April 2020, screening LDCTs fell by 72–78% at one US institution and lung cancer diagnoses were down 39.1%.

show abstract

“…This situation has resulted in a lack of comparison among different classification methods. Researchers also reported that breast cancer risk factors are related to culture and society [4,[17][18][19]. Therefore, local and public mammogram datasets are needed to help researchers detect and classify automatic breast cancer systems in women in Saudi Arabia, especially in the early stages.…”

Section: Discussionmentioning

confidence: 99%

King Abdulaziz University Breast Cancer Mammogram Dataset (KAU-BCMD)

Alsolami

Shalash

Alsaggaf

et al. 2021

Data

View full text Add to dashboard Cite

The current era is characterized by the rapidly increasing use of computer-aided diagnosis (CAD) systems in the medical field. These systems need a variety of datasets to help develop, evaluate, and compare their performances fairly. Physicians indicated that breast anatomy, especially dense ones, and the probability of breast cancer and tumor development, vary highly depending on race. Researchers reported that breast cancer risk factors are related to culture and society. Thus, there is a massive need for a local dataset representing breast cancer in our region to help develop and evaluate automatic breast cancer CAD systems. This paper presents a public mammogram dataset called King Abdulaziz University Breast Cancer Mammogram Dataset (KAU-BCMD) version 1. To our knowledge, KAU-BCMD is the first dataset in Saudi Arabia that deals with a large number of mammogram scans. The dataset was collected from the Sheikh Mohammed Hussein Al-Amoudi Center of Excellence in Breast Cancer at King Abdulaziz University. It contains 1416 cases. Each case has two views for both the right and left breasts, resulting in 5662 images based on the breast imaging reporting and data system. It also contains 205 ultrasound cases corresponding to a part of the mammogram cases, with 405 images as a total. The dataset was annotated and reviewed by three different radiologists. Our dataset is a promising dataset that contains different imaging modalities for breast cancer with different cancer grades for Saudi women.

show abstract

Outcomes by Race in Breast Cancer Screening With Digital Breast Tomosynthesis Versus Digital Mammography

Cited by 26 publications

References 26 publications

Cancer statistics for African American/Black People 2022

Cancer statistics for African American/Black People 2022

US Cancer Screening Recommendations: Developments and the Impact of COVID-19

King Abdulaziz University Breast Cancer Mammogram Dataset (KAU-BCMD)

Contact Info

Product

Resources

About